Tarsus Pharmaceuticals reports Q1 EPS (64c), consensus (63c)

Reports Q1 revenue $78.34M, consensus $72.47M. As of March 31, the company’s cash, cash equivalents and marketable securities were $407.9M. The company said, “Tarsus has entered 2025 with incredible momentum, driven by strong execution of our category-creating strategic blueprint for success and a focused commitment to leadership in eye care. The XDEMVY launch is continuing to exceed our expectations and is on track to potentially become one of the best-selling anterior segment medicines. Building on a foundation of strong commercial performance and the success of our recent equity offering, we believe we are well positioned to accelerate the growth of XDEMVY, create another new category in Ocular Rosacea and continue to advance our pipeline.”